Jazz Pharmaceuticals, Inc.
JAZZJazz Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing and commercializing innovative medicines for conditions such as narcolepsy, epilepsy, and cancer. Founded in 2003, it specializes in neuroscience and oncology, aiming to improve patients' quality of life through specialized therapies.
Company News
Zymeworks Inc. will participate in two upcoming healthcare investor conferences in Miami, including one-on-one meetings and fireside chats, highlighting their biotechnology portfolio and licensed healthcare assets.
Zymeworks, Jazz Pharmaceuticals, and BeOne Medicines reported positive Phase 3 trial results for Ziihera in treating HER2-positive gastroesophageal adenocarcinoma, demonstrating significant improvements in progression-free and overall survival.
Billionaire Seth Klarman's Baupost Group significantly reduced its stake in Alphabet (Google's parent company) while increasing its position in Jazz Pharmaceuticals, a historically cheap and under-the-radar drugmaker.
UBS revised its price target for Jazz Pharmaceuticals to $113 from $117, citing challenges within the company's Sleep franchise and the failure of its Essential Tremor treatment in a clinical trial.
Alnylam Pharmaceuticals (ALNY) and Alimera Sciences, Inc. (ALIM) are in the spotlight following study and merger updates, respectively.
